Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscien...(IS-LL compared to placebo (p value 0.004...),Health

SB-509 has been shown to have effects on angiogenesis, or blood vessel growth, as well as nerve protection and regeneration. When the severity of vascular disease in the 601 study's subjects was taken into account using baseline levels of plasma ICAM-1, a marker of vascular damage, SB-509-treated subjects with more severe vascular disease (higher ICAM-1 levels) showed a statistically significant (p value= 0.01) improvement in mean sural NCV change from baseline compared to placebo treated, providing strong support for both a neuroregenerative and angiogenic mechanism of action of SB-509.

Other Sangamo Abstracts Presented at Society for Neuroscience Meeting

In addition to the presentation of Sangamo's data from its SB-509 clinical program in diabetic neuropathy, data were presented from its preclinical programs in Parkinson's disease and spinal cord injury:

Tuesday, October 20, 2009

• "An engineered zinc finger transcriptional activator of the glial cell line-derived neurotrophic factor provides functional neuroprotection in a rat model of Parkinson's disease." H. S. Zhang(1), J. Laganiere(1), A. P. Kells(2), Q. Yu(1), D. Paschon(1), J. Lai(1), P. D. Gregory(1), K. S. Bankiewicz(2), J. Forsayeth(2); (1) Therapeut. Gene Regulation, Sangamo BioSciences Inc., Richmond, CA; (2) Dept. of Neurolog. Surgery, Univ. of California San Francisco, San Francisco, CA
  

Researchers observed in vivo efficacy in an animal model of Parkinson's disease, demonstrating functional neuroprotection provided by upregulation of GDNF using a ZFP transcription factor (ZFP TF) activator. This study was funded by the Michael J Fox Foundation for Parkinson's Research

• "Examining the therapeutic potential of VEGF-A gene therapy when administered in a delayed fashion following spinal cord injury" S. A. Figley(1), Y. Liu(2), K. S
  '/>"/>